Literature DB >> 29350283

Epigenetic regulation of neuroblastoma development.

Kaat Durinck1, Frank Speleman2.   

Abstract

In recent years, technological advances have enabled a detailed landscaping of the epigenome and the mechanisms of epigenetic regulation that drive normal cell function, development and cancer. Rather than merely a structural entity to support genome compaction, we now look at chromatin as a very dynamic and essential constellation that is actively participating in the tight orchestration of transcriptional regulation as well as DNA replication and repair. The unique feature of chromatin flexibility enabling fast switches towards more or less restricted epigenetic cellular states is, not surprisingly, intimately connected to cancer development and treatment resistance, and the central role of epigenetic alterations in cancer is illustrated by the finding that up to 50% of all mutations across cancer entities affect proteins controlling the chromatin status. We summarize recent insights into epigenetic rewiring underlying neuroblastoma (NB) tumor formation ranging from changes in DNA methylation patterns and mutations in epigenetic regulators to global effects on transcriptional regulatory circuits that involve key players in NB oncogenesis. Insights into the disruption of the homeostatic epigenetic balance contributing to developmental arrest of sympathetic progenitor cells and subsequent NB oncogenesis are rapidly growing and will be exploited towards the development of novel therapeutic strategies to increase current survival rates of patients with high-risk NB.

Entities:  

Keywords:  Chromatin remodeling; Core regulatory circuits; Epigenetic therapy; Histone code; Non-coding RNA

Mesh:

Substances:

Year:  2018        PMID: 29350283     DOI: 10.1007/s00441-017-2773-y

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  137 in total

1.  Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas.

Authors:  Masanobu Abe; Frank Westermann; Akira Nakagawara; Tsuyoshi Takato; Manfred Schwab; Toshikazu Ushijima
Journal:  Cancer Lett       Date:  2006-06-06       Impact factor: 8.679

2.  Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.

Authors:  Laurel T Bate-Eya; Hinco J Gierman; Marli E Ebus; Jan Koster; Huib N Caron; Rogier Versteeg; M Emmy M Dolman; Jan J Molenaar
Journal:  Eur J Cancer       Date:  2017-02-17       Impact factor: 9.162

3.  CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas.

Authors:  Masanobu Abe; Miki Ohira; Atsushi Kaneda; Yukiko Yagi; Seiichiro Yamamoto; Yoshihiro Kitano; Tsuyoshi Takato; Akira Nakagawara; Toshikazu Ushijima
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

4.  Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.

Authors:  Miguel Alaminos; Veronica Davalos; Nai-Kong V Cheung; William L Gerald; Manel Esteller
Journal:  J Natl Cancer Inst       Date:  2004-08-18       Impact factor: 13.506

5.  CHD5 is a tumor suppressor at human 1p36.

Authors:  Anindya Bagchi; Cristian Papazoglu; Ying Wu; Daniel Capurso; Michael Brodt; Dailia Francis; Markus Bredel; Hannes Vogel; Alea A Mills
Journal:  Cell       Date:  2007-02-09       Impact factor: 41.582

Review 6.  Histone methyltransferases in cancer.

Authors:  Mareike Albert; Kristian Helin
Journal:  Semin Cell Dev Biol       Date:  2009-11-03       Impact factor: 7.727

7.  MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A.

Authors:  Kristina Althoff; Anneleen Beckers; Andrea Odersky; Pieter Mestdagh; Johannes Köster; Isabella M Bray; Kenneth Bryan; Jo Vandesompele; Frank Speleman; Raymond L Stallings; Alexander Schramm; Angelika Eggert; Annika Sprüssel; Johannes H Schulte
Journal:  Int J Cancer       Date:  2013-03-07       Impact factor: 7.396

8.  Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma.

Authors:  Stefano Amente; Giorgio Milazzo; Maria Cristina Sorrentino; Susanna Ambrosio; Giacomo Di Palo; Luigi Lania; Giovanni Perini; Barbara Majello
Journal:  Oncotarget       Date:  2015-06-10

Review 9.  Long noncoding RNAs in cancer: mechanisms of action and technological advancements.

Authors:  Nenad Bartonicek; Jesper L V Maag; Marcel E Dinger
Journal:  Mol Cancer       Date:  2016-05-27       Impact factor: 27.401

10.  LSD1 mediates MYCN control of epithelial-mesenchymal transition through silencing of metastatic suppressor NDRG1 gene.

Authors:  Susanna Ambrosio; Stefano Amente; Carmen D Saccà; Mario Capasso; Raffaele A Calogero; Luigi Lania; Barbara Majello
Journal:  Oncotarget       Date:  2017-01-17
View more
  19 in total

1.  miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma.

Authors:  Holly Holliday; Jessica Yang; Eoin Dodson; Iva Nikolic; Alvin Kamili; Madeleine Wheatley; Niantao Deng; Sarah Alexandrou; Thomas P Davis; Maria Kavallaris; C Elizabeth Caldon; Joshua McCarroll; Katleen De Preter; Pieter Mestdagh; Glenn M Marshall; Kaylene J Simpson; Jamie Fletcher; Alexander Swarbrick
Journal:  Mol Ther       Date:  2022-01-05       Impact factor: 11.454

2.  5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype.

Authors:  Mark A Applebaum; Erin K Barr; Jason Karpus; Ji Nie; Zhou Zhang; Amy E Armstrong; Sakshi Uppal; Madina Sukhanova; Wei Zhang; Alexandre Chlenski; Helen R Salwen; Emma Wilkinson; Marija Dobratic; Robert Grossman; Lucy A Godley; Barbara E Stranger; Chuan He; Susan L Cohn
Journal:  JCO Precis Oncol       Date:  2019-05-16

3.  Downregulation of CDKL1 suppresses neuroblastoma cell proliferation, migration and invasion.

Authors:  Weiyi Li; Jing Cao; Jian Liu; Wenli Chu; Congqing Zhang; Shuiling Chen; Zefeng Kang
Journal:  Cell Mol Biol Lett       Date:  2019-03-07       Impact factor: 5.787

4.  Identification of α-N-catenin as a novel tumor suppressor in neuroblastoma.

Authors:  Jingbo Qiao; Eric J Rellinger; Kwang Woon Kim; Camille M Powers; Sora Lee; Hernan Correa; Dai H Chung
Journal:  Oncotarget       Date:  2019-08-20

5.  H19 gene polymorphisms and neuroblastoma susceptibility in Chinese children: a six-center case-control study.

Authors:  Yong Li; Zhen-Jian Zhuo; Haiyan Zhou; Jiabin Liu; Jiao Zhang; Jiwen Cheng; Haixia Zhou; Suhong Li; Ming Li; Jun He; Zhenghui Xiao; Jing He; Yaling Xiao
Journal:  J Cancer       Date:  2019-10-18       Impact factor: 4.207

6.  Acetate supplementation restores chromatin accessibility and promotes tumor cell differentiation under hypoxia.

Authors:  Yang Li; Joshua J Gruber; Ulrike M Litzenburger; Yiren Zhou; Yu Rebecca Miao; Edward L LaGory; Albert M Li; Zhen Hu; Michaela Yip; Lori S Hart; John M Maris; Howard Y Chang; Amato J Giaccia; Jiangbin Ye
Journal:  Cell Death Dis       Date:  2020-02-06       Impact factor: 8.469

Review 7.  Genetic Predisposition to Neuroblastoma.

Authors:  Erin K Barr; Mark A Applebaum
Journal:  Children (Basel)       Date:  2018-08-31

Review 8.  Novel Therapies for Relapsed and Refractory Neuroblastoma.

Authors:  Peter E Zage
Journal:  Children (Basel)       Date:  2018-10-31

9.  miR-34b/c rs4938723 T>C Decreases Neuroblastoma Risk: A Replication Study in the Hunan Children.

Authors:  Yong Li; Zhen-Jian Zhuo; Haiyan Zhou; Jiabin Liu; Zhenghui Xiao; Yaling Xiao; Jing He; Zan Liu
Journal:  Dis Markers       Date:  2019-09-10       Impact factor: 3.434

10.  Epigenetic deregulation of GATA3 in neuroblastoma is associated with increased GATA3 protein expression and with poor outcomes.

Authors:  Bader Almutairi; Jessica Charlet; Anthony R Dallosso; Marianna Szemes; Heather C Etchevers; Karim T A Malik; Keith W Brown
Journal:  Sci Rep       Date:  2019-12-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.